Quantcast

Concise Analysis of the International Atrial Fibrillation Market - Forecast to 2019 - abc27 WHTM

Concise Analysis of the International Atrial Fibrillation Market - Forecast to 2019

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE Research and Markets

DUBLIN, Feb. 26, 2014 /PRNewswire/ --

Research and Markets

(

http://www.researchandmarkets.com/research/rt7832/atrial

) has announced the addition of the

"Concise Analysis of the International Atrial Fibrillation Market - Forecast to 2019"

report to their offering.



(Logo: http://photos.prnewswire.com/prnh/20130307/600769)

The atrial fibrillation market on the basis of geography is segmented into four regions namely North America, Asia-Pacific, Europe and rest of the world (RoW). The North American atrial fibrillation market held the majority of the market share in 2012 on account of the following factors:



High prevalence of atrial fibrillation. According to the estimates of the U.S. CDC, the prevalence of atrial fibrillation was 2.66 million in 2010. Moreover, its prevalence is estimated to reach 12 million by 2050.



The high atrial fibrillation prevalence coupled with the presence of high disposable incomes of patients, the presence of a robust reimbursement infrastructure and rising healthcare expenditure are some of the major factors driving the growth of North America atrial fibrillation market.



The North American region was followed by Europe in terms of market share in 2012. The Asia-Pacific atrial fibrillation market is expected to grow at the highest CAGR on account of the rising prevalence of atrial fibrillation in China coupled with the introduction of new healthcare reforms and rapid economic development in the country.



In terms of treatment types, the overall atrial fibrillation market is segmented into two type's namely pharmacological and non-pharmacological treatment markets. The global atrial fibrillation treatment market was dominated by the pharmacological treatment procedures (involving anti-arrhythmic drugs, rate control drugs, chemical cardioversion and anti-coagulants) in terms of market share in 2012. This valuation is justified by the following reasons:



Drugs are consumed more frequently by patients, sometimes simultaneously with non-pharmacological treatment procedures.



Key Topics Covered:



1 Preface



2 Executive Summary



3 Market Overview



4 Atrial Fibrillation Market, by Treatment Types



5 Atrial Fibrillation Market, by Geography



6 Competitive Landscape



7 Recommendations



8 Company Profiles



Companies Mentioned:

  • AtriCure
  • Biosense Webster
  • Boehringer Ingelheim
  • Boston Scientific Corporation
  • Bristol-Myers Squibb Corporation
  • CardioFocus
  • Endoscopic Technologies
  • Johnson and Johnson Ltd
  • Sanofi Aventis
  • St Jude Medical

For more information visit http://www.researchandmarkets.com/research/rt7832/atrial

Media Contact: Laura Wood , +353-1-481-1716, press@researchandmarkets.net

©2012 PR Newswire. All Rights Reserved.

Powered by WorldNow